Head and Neck Cancers
If it’s your first time on this website, please read the disclaimer section.
Jun 01 – Jun 08, 2026
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.
NAT MED · Q1 JOURNAL - RANK #1/195TOP-TIER
This phase 1 first-in-human trial evaluated IMA401, a TCR-based bispecific T cell engager targeting MAGE-A4/MAGE-A8, in 61 patients with recurrent or refractory solid tumors. The recommended phase 2 dose was established at 1-2 mg biweekly, with a manageable safety profile featuring 38% grade 1-2 cytokine release syndrome and no maximum tolerated dose reached. Efficacy results showed a 20% objective response rate at the recommended dose across multiple indications, notably reaching 29% in head and neck cancer patients. These findings demonstrate the clinical potential of the bispecific TCER platform as a promising immunotherapy for advanced malignancies.
10.1038/s41591-026-04455-x
Amivantamab in recurrent/metastatic HNSCC after checkpoint inhibitor and chemotherapy: pivotal results from the phase 1b/2 OrigAMI-4 study.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This phase 1b/2 study evaluated amivantamab, an EGFR-MET bispecific antibody, in 102 patients with recurrent/metastatic head and neck squamous cell carcinoma after prior checkpoint inhibitor and platinum chemotherapy. The primary endpoint of objective response rate (ORR) by blinded independent review was 42% (95% CI, 32-52), including a 15% complete response rate, with a median progression-free survival of 6.8 months and overall survival of 12.5 months. These outcomes exceed the typical 21-24% ORR seen with single-agent paclitaxel or cetuximab in this refractory population, offering a novel targeted therapy option. For a clinician focused on cancer research, this provides high-level evidence for a new treatment strategy in a difficult-to-treat malignancy, though results require confirmation in larger randomized trials.
10.1200/JCO-26-01042
May 25 – Jun 01, 2026
Cancer Diagnostic Delay Rates Associated With a Population-Based Screening Trial Evaluating a Cell-Free DNA Multicancer Early Detection Test.
JAMA-J AM MED ASSOC · Q1 JOURNAL - RANK #4/332TOP-TIER
This cross-sectional study used a difference-in-differences design to evaluate whether regional participation in the NHS-Galleri multicancer early detection (MCED) trial affected cancer diagnostic delay rates across 21 regions in England. In the first six months, participating regions saw diagnostic delay rates rise from 28.6% to 29.6%, while non-participating regions decreased from 28.9% to 26.3%, representing a 3.4 percentage point adjusted difference (P < .001). The study highlights that large-scale cancer screening trials can increase system-level demand, evidenced by a 4.8 percentage point increase in delays during the second six-month period and higher referral rates. Clinicians and health systems must account for these “spillover effects” on existing cancer diagnostic pathways when implementing population-based screening interventions to ensure timely care for all suspected cancer patients.
10.1001/jama.2026.6803
Longitudinal Risk for Suicidal Self-Directed Violence Among Veterans With Cancer.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This national cohort study assessed longitudinal risks and methods for suicidal self-directed violence (SSDV) among 292,271 veterans with invasive solid or hematologic cancer (2014-2023) using registries. Overall, 2400 SSDV events occurred (203 per 100,000 person-years), with poisoning most common (26%). High rates were found in patients with CNS, pancreas, head and neck, liver and biliary system, and thyroid cancers, advanced cancer (261 per 100,000 person-years), severe frailty, chronic mental illness, and high pain scores. Risks persisted five years post-diagnosis for younger (≤45 years), unmarried, advanced cancer, and CNS cancer patients, highlighting vulnerable subgroups. This emphasizes the critical need for systematic tracking of suicidal behaviors and tailored screening strategies within comprehensive cancer care, especially for these high-risk populations.
10.1001/jamaoncol.2026.1459
May 04 – May 11, 2026
Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This phase I/Ib trial investigated ficerafusp alfa plus pembrolizumab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) overexpressing PD-L1, assessing safety, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). Among 42 patients, 45% experienced grade ≥3 treatment-related adverse events. Confirmed ORRs were 54% (21% complete response) for HPV-negative (n=28) and 27% for HPV-positive (n=11) tumors. For HPV-negative patients, median PFS was 9.9 months and median OS was 21.3 months, demonstrating promising antitumor activity directly relevant to cancer treatment. This combination shows favorable safety and efficacy, particularly in HPV-negative R/M HNSCC, suggesting a potential new first-line therapeutic strategy for this challenging cancer population.
10.1200/JCO-25-02027
Apr 27 – May 04, 2026
An agentic framework for autonomous scientific discovery in cancer pathology.
NAT MED · Q1 JOURNAL - RANK #1/195TOP-TIER
This study introduces SPARK, an agentic AI framework that uses natural language to autonomously generate biologically driven analytical tools for tumor pathology without extra model training. Evaluated across 18 cohorts with over 5,400 patients spanning five cancer types, SPARK produced clinically relevant concepts correlated with prognosis, pathological variables, and predictive biomarkers, including inferred tumor progression from static images. The framework directly addresses the clinician’s interest in cancer-focused research by demonstrating applicability in lung, colorectal, breast, and oropharyngeal cancers, with evidence of prognostic and predictive value. Primary implications include potential to enhance diagnostic precision and biological insight, though prospective clinical validation is still needed before routine use.
10.1038/s41591-026-04357-y
Apr 06 – Apr 13, 2026
Nine-Valent Human Papillomavirus Vaccination and Related Cancers in Males.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This multicenter retrospective cohort study evaluated the effectiveness of the 9-valent HPV vaccine in preventing HPV-related cancers in males aged 9-26 years, finding vaccinated males had a 46% lower risk of developing composite HPV-related cancers (HR 0.54, 95% CI 0.37-0.81) compared to unvaccinated males over up to 10 years of follow-up. The study’s primary focus was on cancer prevention, specifically head and neck, esophageal, anal, and penile cancers, with significant risk reduction maintained across age subgroups (9-14 years: HR 0.58; 15-26 years: HR 0.50). These results directly address cancer prevention as a primary research focus by demonstrating vaccine effectiveness against multiple cancer types. The findings strongly support implementing sex-neutral HPV vaccination policies to reduce the future burden of HPV-associated cancers in males.
10.1001/jamaoncol.2026.0496
Mar 30 – Apr 06, 2026
Medial retropharyngeal nodal region sparing radiotherapy in nasopharyngeal carcinoma: five year analysis of open label, non-inferiority, multicentre, randomised phase 3 trial.
BMJ-BRIT MED J · Q1 JOURNAL - RANK #5/332TOP-TIER
This multicenter, randomized phase 3 trial evaluated the five-year efficacy and safety of sparing the medial retropharyngeal lymph node (MRLN) region during radiotherapy for 568 patients with non-metastatic nasopharyngeal carcinoma. Results demonstrated non-inferiority, with five-year local relapse-free survival at 89.2% for the MRLN sparing group versus 90.6% for the standard group (P=0.90) and significantly lower rates of grade ≥1 dysphagia (22% vs 32%, P=0.01). The sparing technique significantly improved swallowing-related quality of life and reduced objective measures of pharyngeal dysfunction, such as aspiration (12% vs 29%) and pharyngeal muscle atrophy. These findings support MRLN sparing radiotherapy as a new standard of care for patients without MRLN involvement, effectively balancing oncologic control with long-term functional preservation.
10.1136/bmj-2025-086050
Systemic Treatment of Thyroid Cancer: ASCO Guideline.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This ASCO guideline provides evidence-based recommendations for the systemic treatment of various thyroid cancer types, developed by a multidisciplinary Expert Panel through a comprehensive literature search of 66 publications. The panel formulated recommendations for systemic therapy in well-differentiated, differentiated high-grade or poorly differentiated, anaplastic, and medullary thyroid cancers. This guideline is highly relevant to clinicians interested in cancer, as it directly addresses the management of a specific cancer type, providing crucial guidance on systemic treatment options. It offers practical, evidence-based recommendations for clinicians to optimize systemic therapy decisions, improving patient outcomes in various forms of thyroid cancer.
10.1200/JCO-26-00235
Mar 23 – Mar 30, 2026
Proton beam therapy for oropharyngeal cancer (TORPEdO): a phase 3, randomised controlled trial.
LANCET · Q1 JOURNAL - RANK #1/332TOP-TIER
This phase 3 randomized controlled trial (TORPEdO) compared intensity-modulated proton therapy (IMPT) with intensity-modulated radiation therapy (IMRT) for locally advanced oropharyngeal squamous cell carcinoma, assessing late functional, patient-reported, disease control, and survival outcomes. At 12 months, gastrostomy-tube dependence was 2% in both groups, severe weight loss was 18% in IMPT vs 6% in IMRT (p=0.079), and UW-QoL physical composite scores were similar (IMPT 78.3 vs IMRT 77.1, p=0.56). At a median follow-up of 28.3 months, 24-month freedom from loco-regional recurrence was 94% (IMPT) vs 97% (IMRT) (HR 2.6, p=0.24), and overall survival was 95% in both groups (HR 1.6, p=0.47). The study directly addresses cancer treatment by comparing two radiation modalities for oropharyngeal cancer, evaluating their impact on disease control, survival, and patient quality of life. The findings suggest IMPT and IMRT yield similar outcomes, reinforcing IMRT as the standard of care in settings where IMPT is not routinely used.
10.1016/S0140-6736(26)00314-4
Mar 16 – Mar 23, 2026
Fullerene for Reducing Acute Radiation Dermatitis in Patients Undergoing Radiotherapy for Head and Neck Cancer: A Phase II, Double-Blind, Randomized Controlled Trial.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This phase II, double-blind, randomized controlled trial investigated fullerene versus trolamine for reducing acute radiation dermatitis (ARD) in 132 head and neck cancer patients undergoing radiotherapy. The study found a significantly lower incidence of grade ≥2 ARD in the fullerene group (34.8%; 95% CI, 24.5 to 46.9) compared to the trolamine group (83.3%; 95% CI, 72.6 to 90.4). This research is highly relevant to cancer care as it addresses a significant debilitating toxicity experienced by head and neck cancer patients receiving essential radiotherapy. Fullerene shows promise as an effective intervention to improve patient tolerability and quality of life during cancer treatment, potentially enhancing adherence to critical radiotherapy regimens.
10.1200/JCO-25-02264
Diagnostic Performance of Anti-Epstein-Barr Virus BNLF2b in Suspected Nasopharyngeal Carcinoma.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This prospective multicenter cohort study evaluated the diagnostic performance of the anti-EBV BNLF2b (P85-Ab) assay compared to traditional biomarkers in 3,777 participants with suspected nasopharyngeal carcinoma (NPC). The P85-Ab assay demonstrated superior diagnostic accuracy with a sensitivity of 93.0% and a specificity of 97.3%, significantly outperforming VCA-IgA, EA-IgA, and EBNA1-IgA which all showed specificities below 90%. For clinicians, this biomarker provides a highly reliable tool for early cancer detection, maintaining high sensitivity even in asymptomatic individuals (92.0%) or those with non-specific symptoms (88.4%). The findings suggest that P85-Ab is a robust standalone biomarker for NPC in outpatient settings, though combining it with other antibodies may further improve sensitivity (95.9%) in patients already presenting with NPC-specific symptoms.
10.1001/jamaoncol.2026.0251
Mar 09 – Mar 16, 2026
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
The LEAP-010 phase III study investigated lenvatinib plus pembrolizumab as first-line therapy for PD-L1 CPS ≥1 recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in a randomized, placebo-controlled, double-blind setting. The combination significantly improved median progression-free survival (6.2 vs 2.8 months; HR 0.64; p=.0001040) and objective response rate (46.1% vs 25.4%; p=.0000251) compared to placebo plus pembrolizumab. However, median overall survival was not improved (15.0 vs 17.9 months; HR 1.15; p=.882), and grade 3-4 adverse events were higher (66.9% vs 38.3%) with the combination. This study directly addresses a treatment strategy for a specific cancer, HNSCC, indicating that while surrogate endpoints improved, the lack of overall survival benefit and increased toxicity suggest this combination may not be a superior first-line option.
10.1200/JCO-25-00570
Mar 02 – Mar 09, 2026
Development of a Classifier for Metabolic Subtypes of Nasopharyngeal Carcinoma to Guide Personalized Immunotherapy Strategies: Biomarker Analysis of the Phase III CONTINUUM and DIPPER Trials.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This study aimed to identify biomarkers predictive of immunotherapy benefits in locoregionally advanced nasopharyngeal carcinoma (NPC) by performing RNA sequencing on tumor samples from 407 patients across two phase III trials to develop a metabolic gene-based classifier. Three distinct metabolic subtypes were identified, with the MS1 subtype showing a significant improvement in 3-year event-free survival (EFS) when anti-PD-1 was added to chemoradiotherapy (90.2% vs 69.6%; HR, 0.27), while MS2 and MS3 derived no significant benefit. These findings are highly relevant to cancer research as they provide a novel molecular classification for NPC, directly impacting personalized treatment strategies for this specific cancer. This classifier offers a promising predictive biomarker to guide treatment decisions, potentially optimizing immunotherapy use and improving outcomes for patients with locoregionally advanced NPC.
10.1200/JCO-25-02111